| Biomarker ID | 1440 |
| PMID | 24909936 |
| Year | 2014 |
| Biomarker | MUC1 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Increased with Increased mortality |
| Odds Ratio/Hazard Ratio/Relative Risk | Mortality Rate Ratios: MRR: 2.51 (95% CI 1.14–5.54) |
| Effect on Pathways | Pathways include: Termination of O-glycan biosynthesis, Interleukin-11 pathway, O-linked glycosylation of mucins, Post-translational protein modification, Protein metabolism |
| Experiment | PCa Specific Mortality Vs No Mortality |
| Type of Biomarker | Prognostic |
| Cohort | Subjects were identified from three Australian epidemiological studies. Men who had died of their disease, “cases†(N = 83), were matched to “referents†(N = 232), those who had not died of prostate cancer, using incidence density sampling. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.02 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |